The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

This study is testing whether combining standard chemotherapy (gemcitabine + cisplatin) and immunotherapy (durvalumab) with a targeted liver procedure called Y-90 (yttrium-90 radioembolization, which delivers radiation directly into liver tumors) works better than chemotherapy and immunotherapy alone for bile duct cancer that cannot be removed surgically. **You may be eligible if:** - You are at least 18 years old - You have been diagnosed with intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) confirmed by biopsy - Your cancer cannot be surgically removed - Your cancer has not spread outside the liver (except nearby lymph nodes) - You have not previously received treatment for this cancer, or your previous treatment was at least 6 months ago - Your liver does not have cirrhosis - Your overall health and organ function are adequate **You may NOT be eligible if:** - You are pregnant or breastfeeding - Your cancer has spread to other organs beyond nearby lymph nodes - Your liver is cirrhotic - You cannot tolerate the procedures involved in the trial Talk to your doctor to see if this trial is right for you.